Patent ID: 7435409
Filing Date: 2008-10-14
Classification: A61K,A61Q

Abstract:
1. An oral liquid composition for reducing nerve sensitivity comprising: (a) from about 0.01% by weight to about 5% by weight of an orally-acceptable, soluble potassium salt; (b) from about 0.01% by weight to about 10% by weight of a sodium (C 8 -C 24 ) alkylsulfate; (c) from about 0.01% by weight to about 20% by weight of an orally-acceptable polar surfactant, said surfactant selected from the group consisting of a C 6 -C 30 ), fatty acid mono or diester of ethoxylated sorbitan, a (C 6 -C 30 ) fatty acid diester of polyethylene glycol, a sodium salt of a (C 6 -C 30 ) fatty acyl sarcosinate, a (C 6 -C 30 ) fatty acyl ester of sarcosine acid, a sodium salt of a (C 6 -C 30 ) fatty acyl taurate, a sodium salt of a (C 6 -C 30 ) fatty acyl methyltaurate, a (C 6 -C 30 ) fatty acyl ester of taurine, a (C 6 -C 30 ) fatty acyl ester of methyltaurine acid, a (C 6 -C 30 ) fatty acyl betaine, a (C 6 -C 30 ) fatty acyl quaternary ammonium chloride, dimethicone copolyols, polydimethylsiloxane phosphate esters, polydimethylsiloxane copolyol phosphate esters, polydimethylsiloxane phosphobetaines, polydimethylsiloxane copolyol phosphobetaines, polydimethylsiloxane taurates, polydimethylsiloxane copolyol taurates, acetylated polydimethylsiloxane copolyols, and polydimethylsiloxane quaternium compounds, polydimethylsiloxane copolyol quaternium compounds; and (d) an orally-acceptable aqueous vehicle comprising from about 50% by weight to about 85% by weight water; wherein the potassium salt is dissolved in the composition and wherein the molar ratio of the surfactant of (c) to the sodium (C 8 -C 24 ) alkylsulfate is greater than or equal to about 1:1 such that when a.), b.), c) are dissolved in d.), the resultant composition is free of visible potassium alkyl sulfate precipitates.